Article Figures & Data
Figures
- FIGURE 1.
CONSORT (Consolidated Standards of Reporting Trials) flow diagram for patient inclusion in data analysis.
- FIGURE 2.
Median OS of full analysis set and patient subsets. (A) OS of full analysis set (n = 154) was 20.0 mo (95% CI, 10.0–30.0). (B) At 36.0 mo (95% CI, 21.3–50.7), OS of PET/CT set (18F-FDG PET/CT at initial diagnostic workup, n = 76) was significantly higher than OS of comparator set (without 18F-FDG PET/CT at initial diagnostic workup, n = 78), at 12.0 mo (95% CI, 8.7–15.3; P < 0.001).
- FIGURE 3.
Multivariate analysis for prognostic parameters for PET/CT set (n = 76): hazard ratio with 95% CI and P value. *P < 0.05. **P < 0.01. HR = hazard ratio; NEC = neuroendocrine carcinoma).
- FIGURE 4.
Median OS in relation to SUVmax in PET/CT set. In subset with initial 18F-FDG PET/CT, patients with SUVmax above 20 (n = 22) had significantly higher OS (not reached) than patients with SUVmax of 20 or less (n = 54) (32.0 mo; 95% CI, 23.2–40.8; P = 0.022).
Tables
Full analysis set (n = 154) PET/CT set (n = 76) Comparator set (n = 78) Parameter Characteristic n % n % n % Sex Male 82 53.25 41 53.95 41 52.56 Female 72 46.75 35 46.05 37 47.44 Age >60 y 84 54.55 39 51.32 45 57.69 ≤60 y 70 45.45 37 48.68 33 42.31 Metastasis Solitary 61 39.61 40 52.63 21 26.92 Diffuse 93 60.39 36 47.37 57 73.08 Histology Adenocarcinoma 66 42.86 25 32.89 41 52.56 Undifferentiated carcinoma 10 6.49 6 7.89 4 5.13 Squamous cell carcinoma 53 34.42 40 52.63 13 16.67 Neuroendocrine carcinoma 25 16.23 5 6.58 20 25.64 Secondary malignancy Yes 32 20.78 14 18.42 18 23.08 No 122 79.22 62 81.58 60 76.92 Pulmonary artery embolism or thrombosis Yes 28 18.18 13 17.11 15 19.23 No 126 81.82 63 82.89 63 80.77 Affected organ systems 1 83 53.90 47 61.84 36 46.15 2 41 26.62 20 26.32 21 26.92 ≥3 30 19.48 9 11.84 21 26.92 SUVmax >20 22 28.95 ≤20 54 71.05 Median age was 62 y (range, 20–85 y). Median SUVmax was 13.9 (range, 3.5–30.8).
Supplemental Data
Files in this Data Supplement:
